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SUMMARY
Purpose—We sought to determine the association of C/EBPα expression status with clinical,
pathologic and molecular characteristics, as well as outcomes, in non-small-cell lung cancer
(NSCLC). This is the first comprehensive study of this transcription factor in patients with
NSCLC.
Patients and Methods—Our cohort originated from ECOG 3590 (randomized trial of
postoperative adjuvant therapy with thoracic radiation or cisplatin and etoposide plus thoracic
radiation in patients with completely resected stages II and IIIA NSCLC; and its laboratory
correlate, ECOG 4592). 164 tumor samples contained sufficient material for
immunohistochemical (IHC) analysis. C/EBPα tumor staining was compared to that of basal
bronchial cells (3+). 0 or 1+ (weak) suggested lack of, while 2 or 3+ (strong) suggested C/EBPα
expression.
Results—90 tumors (55%) had 0 or 1+ C/EBPα staining, and the remaining 74 (45%) 2 or 3+.
Patients with squamous cell carcinomas had a higher percentage of weak C/EBPα IHC staining
compared to other histologies (p=0.048) and there was a trend for loss of C/EBPα in poorly
differentiated compared to well differentiated tumors (p=0.07). There was no association between
C/EBPα IHC and mutations in p53 or K-ras. The median disease-free survival for patients with
weak and strong C/EBPα IHC expression was 29.6 and 30.6 months, respectively (p=0.94). The
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median overall survival between the weak and strong groups was 43.5 and 38.5 months,
respectively (p=0.83).
Conclusions—Loss of expression of C/EBPα is seen in over half of stage II and IIIA NSCLC,
specifically in squamous cell carcinomas and poorly differentiated tumors. Since down-regulation
of C/EBPα is a common event in NSCLC, further elucidation of the involvement of C/EBPα in
the pathogenesis and progression of lung cancer may identify novel therapeutic targets.
Keywords
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INTRODUCTION
Lung cancer continues to be the leading cause of death from cancer in the United States (1).
Complete surgical resection, whenever feasible, is generally recognized as the most effective
initial treatment for non–small-cell lung cancer (NSCLC). However less than one third of
patients present with early-stage disease amenable to effective surgical intervention (1,2).
Following surgery alone, the 5-year survival for patients with pathological stage IB, II and
IIIA NSCLC is still disappointing at 60%, 40–50% and 25%, respectively (2). Adjuvant
chemotherapy with platinum-based doublets has been shown to improve survival in well-
conducted randomized trials (3–6). The overall 5-year survival improvement in these studies
ranged from 5 to 15% (3,4,6). Despite the recognized association of clinical and pathologic
characteristics (age, weight loss, performance status, tumor-node-metastasis staging system)
with prognosis, these parameters alone do not predict which patients are prone to develop
recurrent disease and do not identify patients who will benefit from adjuvant therapy (2,4,7).
The search for novel prognostic and predictive markers is essential to improve patient
selection in early-stage NSCLC for adjuvant treatment strategies, as well as for the
discovery of new therapeutic targets.
During the last decade numerous oncogenes and tumor suppressor genes implicated in the
pathogenesis of lung cancer have been identified (8). The prognostic significance of these
newly described genes has been studied in small retrospective series with conflicting results
(9–13). The few studies that employed well-established prospective databases of patients
with resected NSCLC have frequently shown a lack of significant prognostic information.
As an example, mutations in the K-ras oncogene (implicated in signal transduction
pathways) and the p53 tumor suppressor gene (involved in cell-cycle regulation) were not
associated with significant prognostic significance in the context of a clinical trial of
adjuvant therapy for completely resected NSCLC (7). Recent studies of factors involved in
metastatic potential, such as vascular endothelial growth factor (VEGF) (14), as well as
recently identified transcription factors, such as early growth response gene 1 (EGR1) (15),
and cytokines (16) have suggested new prognostic markers in early-stage NSCLC. However
validation in well established prospective patient cohorts is still lacking.
The transcription factor CCAAT/enhancer binding protein alpha (C/EBPα) is a tissue-
specific differentiation factor that plays a major role in the terminal differentiation of
myeloid cells, hepatocytes, and adipocytes among others (17,18). The association of C/
EBPα and cancer has been elucidated in acute myeloid leukemia (AML) (19), where C/
EBPα expression is reduced in leukemias carrying the t(8;21) translocation (20) and C/
EBPα mutations confer improved prognosis in a small subgroup of AML patients with
normal cytogenetics (21,22). In epithelial tissues, C/EBPα is expressed in the breast, colon,
prostate, and the respiratory epithelium (23).
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In the lung, C/EBPα is highly expressed in type II pneumocytes as well as cells of the
bronchial epithelium (24,25) and regulates the expression of several key genes during lung
differentiation (26). Abnormal proliferation of type II pneumocytes is seen in the context of
the lethal phenotype of C/EBPα −/− knockout mice (27). In the lung-specific conditional C/
EBPα knockout mouse developed by our group, a block in type II cell differentiation and
increase in respiratory epithelial proliferation is seen (28). We also demonstrated that C/
EBPα is down-regulated in a large proportion of lung cancers, and induction of C/EBPα
expression in lung cancer cell lines led to growth arrest, apoptosis and cellular
differentiation (29). We identified this gene as a novel tumor suppressor gene in lung cancer.
In the primary lung cancer samples analyzed by immunohistochemistry (IHC) specific to C/
EBPα, almost half of the tumors had absent or low expression of this protein (29). Tada and
colleagues also showed the frequent down-regulation of C/EBPα in NSCLC and identified
methylation of the upstream promoter of this gene as the mechanism of silencing. Loss of C/
EBPα is one of the most common genetic events in NSCLC and therefore supports C/EBPα
as a critical tumor suppressor gene in lung cancer (30).
However, it is still unknown if the observed down-regulation of C/EBPα has clinical
significance. In order to investigate the association of C/EBPα expression and clinical,
pathologic and molecular characteristics, as well as the possible prognostic and predictive
role of C/EBPα in lung cancer, we studied the immunohistochemical expression of this
protein in the prospective cohort of patients from E3590 (a trial of postoperative adjuvant
therapy in patients with resected stages II or IIIA NSCLC) (31).
MATERIAL AND METHODS
Patient Study
The samples examined originated from patients who participated in E3590, a prospective
randomized intergroup trial of postoperative adjuvant therapy in patients with completely
resected stages II and IIIA NSCLC (31). Patients were required to have complete resection
of the primary tumor and mediastinal lymph node sampling or dissection. After stratification
for nodal status, weight loss, histology, and lymph node dissection patients were randomized
to receive either radiotherapy alone – arm A, or four cycles of cisplatin (60 mg/m2
intravenously on day 1) and etoposide (120 mg/m2 intravenously days 1 to 3) administered
concurrently with thoracic radiotherapy (50.4 Gy in 28 daily fractions) – arm B (31).
Patients participating in E3590 were also offered enrollment into the ancillary laboratory
study, E4592, provided that at least one paraffin block of primary tumor or a portion of
tumor tissue removed from the block was available from the patient (7). All patients gave
informed consent for both the clinical and laboratory correlative study.
488 patients were entered onto E3590 between April 1991 and February 1997. 217 patients
were registered onto the laboratory correlative study. However, 20 samples were never
submitted (7). Of the 197 samples available, 164 contained sufficient material for
immunohistochemical analysis of C/EBPα expression.
C/EBPα Immunohistochemistry (IHC)
Immunohistochemical studies were performed on formalin-fixed, 5-micron thick paraffin-
embedded tissue specimens using citrate-microwave antigen retrieval (29). In brief, a
dilution (1:500) of a polyclonal rabbit anti-C/EBPα antibody (200 µg/0.1 ml; Santa Cruz
Biotechnology, Santa Cruz, CA) was utilized, and the specificity of the stain confirmed by
the concomitant use of a specific blocking peptide (1:100 dilution, 100 µg/0.5 ml; Santa
Cruz Biotechnology). IHC was performed using Vectastain ABC kits (Vector Laboratories,
Burlingame, CA). The positive staining was visualized by incubating slides with
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diaminobenzadine. Blinded scoring of specimens was performed by an experienced lung
pathologist (OK) and an oncologist (BH), comparing the intensity of tumor staining to the
staining of non-affected basal bronchial cells, which was deemed 3+. Essentially all slides
contained some normal lung tissue and bronchial elements, thereby serving as an internal
control. This strategy was used in our initial lung tissue studies (29). Individual samples had
homogenous C/EBPα nuclear staining in tumor cells. Two separate groups were categorized
for statistical analysis (29). The presence of 2+ (moderate intensity) or 3+ (comparable to
the intensity of the bronchial epithelium) staining was suggestive of C/EBPα expression and
designated as “strong”; the complete absence of staining (0) or faint levels of staining (1+)
were indicative of lack of C/EBPα expression, and labeled “weak”. Examples of each IHC
staining category are depicted in Figure 1.
Statistical Analysis
Fisher’s exact test was utilized to access the association between C/EBPα expression status
with clinical, pathologic and molecular characteristics in E3590. A two-sample t-test was
used to assess the difference between age and IHC score. All tests were two-sided. P-values
≤ 0.05 were considered statistically significant.
We also analyzed differences in disease-free survival and overall survival between the
groups with weak (0 or 1+) or strong (2 or 3+) C/EBPα IHC staining. Overall survival was
calculated as the time from randomization to death from any cause. Patients alive were
censored at the date of last contact. Disease-free survival was defined as time from
randomization to the earliest sign of disease recurrence or death from any cause. Patients
alive without a recurrence reported were censored at the date of last contact. Distributions
for overall survival time and disease-free survival were estimated with the Kaplan-Meier
method (32) and compared with the log-rank test (33).
RESULTS
Patient cohort
Survival data for patients enrolled in E3590 and E4592 have been reported previously
(7,31). Of the original 488 patients of E3590, median follow up is close to 10 years. Median
survival was 38.3 months. For the subgroup of 217 patients enrolled in E4592, median
survival was 40.3 months. There was no statistical difference in survival distributions
between E3590 and E4592 (7).
Among the 164 patients analyzed in the current study, the median overall survival of 40.3
months and median disease-free survival of 30.6 months were not different from those of the
complete study group and its ancillary laboratory study (7,31).
Clinical, pathologic and molecular characteristics in each C/EBPα IHC group
Of the assessable tumor samples, 90 (55%) had either 0 or 1+ (weak) staining for C/EBPα.
The other 74 (45%) were scored as 2+ or 3+ (strong). The clinical, pathologic and molecular
characteristics of the weak and strong C/EBPα IHC groups, as well as treatment arm of
randomization are listed in Table 1. There was no statistical difference in age, sex (a trend of
male sex and the weak C/EBPα IHC group did not reach statistical significance; p=0.16),
TNM stage, and treatment arm between the two IHC groups. A history of tobacco use was
not systematically collected in E3590 and, therefore, no data are available regarding
smoking and C/EBPα IHC in this study.
Patients with squamous cell histology tended to have a higher percentage of weak C/EBPα
IHC staining (37/55, 67%, of the squamous cell carcinoma tumors), when compared to
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adenocarcinoma (44/86, 51%) and other histologies (p=0.048). Histological differentiation
status was available in 88 tumors. Only 1/6 patients with well differentiated tumors had
weak C/EBPα IHC, while 22/39 with poorly differentiated cancers were in the weak IHC
group. Among the remaining 43 moderately differentiated tumors, 22 had strong C/EBPα
IHC. Comparing the well and poorly differentiated cohort, a non-statistical strong trend
towards loss of C/EBPα and less differentiated tumor samples was noted (p=0.07).
There was no statistical correlation between C/EBPα expression and mutations in the tumor
suppressor gene p53 or in the oncogene K-ras (Table 1). However, in the weak C/EBPα IHC
group a non-statistical trend towards wild-type p53 was seen (p=0.16).
Disease-free survival and overall survival in the different C/EBPα IHC groups
Among the 90 patients with weak C/EBPα IHC staining, median disease-free survival was
29.6 months (95% CI, 17.5 to 45.2 months); and for the 74 patients with strong C/EBPα
IHC it was 30.6 months (95% CI, 19.6 to 41.4 months). There was no difference in disease-
free survival by C/EBPα IHC (p=0.94 by log-rank) (Figure 2A).
The median overall survival of the weak and strong C/EBPα IHC groups was 43.5 months
(95% CI, 30.8 to 80.6 months) and 38.5 months (95% CI, 32.5 to 61.0 months), respectively
(p=0.83 by log-rank) (Figure 2B). In April 2006, of the 164 patients, 21% (19/90) were alive
in the weak, and 20% (15/74) in the strong C/EBPα IHC group. When each individual IHC
staining score was analyzed separately (0, 1+, 2+ or 3+) for disease-free and overall survival
there were no statistical differences (data not shown).
When the C/EBPα IHC weak and strong groups were analyzed by treatment arm (arm A,
radiotherapy, and arm B, adjuvant chemoradiotherapy), there was no difference in outcomes.
The median overall survival for the weak and strong C/EBPα IHC groups in arm A was 41.6
months (95% CI, 27.6 to 91.6) and 39.4 months (95% CI, 35.8 to 61.0), respectively (p=
0.97) (Figure 3A). In arm B, it was 40 months (95% CI, 30 to 79.6 months) and 36 months
(95% CI, 21.8 to 65.5 months), respectively (p= 0.84) (Figure 3B).
DISCUSSION
The transcription factor C/EBPα is essential for airway epithelial development (26), due to
its key role in regulating proliferation and differentiation-dependent gene expression of
lung-specific target genes involved in late lung development such as surfactant protein A
and D, clara cell secretory protein and the P450 enzyme CYP2B1, among others (34). In
addition, hyperproliferation and differentiation arrest of type II pneumocytes were seen in a
C/EBPα knockout mice model (27) as well as in the lung-specific conditional mouse model
of C/EBPα deletion developed by our group (28). In fact, the prominent lung phenotype of
our conditional mouse model resulted in respiratory arrest and death (28). Induction of this
gene’s expression in lung cancer cell lines led to growth arrest, apoptosis, and cellular
differentiation (29). These results identified C/EBPα as a master regulator of airway
epithelial maturation and suggested that the loss of this gene could be an important event in
the multistep process of lung carcinogenesis. Furthermore, our group (29) and others (30)
have previously identified down-regulation of C/EBPα in a large proportion of lung cancer
cell lines and primary tumor samples.
The mechanism of down-regulation of C/EBPα in lung cancer has been recently elucidated.
We have shown that C/EBPα mutations are a rare event in lung cancer (only 1 sequence
change in 50 primary NSCLC tumor DNA samples analyzed) (35). Tada et al demonstrated
the epigenetic modulation of this gene in lung cancer (30). Both in lung cancer cell lines and
in patients’ tumors presence of upstream promoter methylation was significantly correlated
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with lack of C/EBPα RNA levels (30). In the pathologic specimens studied, there was a
statistically significant inverse correlation between the density of methylation and loss of C/
EBPα using an IHC method similar to ours (30). These data establish IHC as a possible
surrogate marker of C/EBPα upstream promoter methylation in NSCLC and validate the use
of an IHC method as a marker of C/EBPα expression.
The objective of our project was to assess the frequency of C/EBPα down-regulation in a
large number of prospectively collected stage II and IIIA NSCLC specimens and determine
the association of C/EBPα expression with baseline clinical, pathologic and molecular
characteristics, as well as clinical outcomes. In agreement with previously described IHC
studies of C/EBPα in NSCLC patients (29,30), we identified down-regulation (the weak, 0
or 1+ IHC score) of C/EBPα in 55% of the 164 available samples.
A significantly greater percentage of squamous cell carcinomas in E3590 had down-
regulation of C/EBPα by our immunohistochemical method (67% of the 55 squamous cell
carcinoma samples were in the weak C/EBPα IHC group), while C/EBPα was present in
approximately half of adenocarcinoma samples. In our initial C/EBPα IHC study of 53
heterogeneous lung cancer samples (there were only 9 squamous carcinomas from total) this
pattern was not observed (29), but subsequent analysis of a larger dataset of 122 NSCLCs
revealed an association of greater down-regulation of C/EBPα in squamous cell carcinomas
(30). It is possible that loss of C/EBPα may be an essential step during squamous cell lung
carcinogenesis. Interestingly, loss of C/EBPα seems to be a common finding in squamous
cell carcinomas of the skin (36).
Our current study also disclosed that there were no statistically significant associations
between mutations in p53 or K-ras and C/EBPα status, however there was a trend towards
more p53 mutations in the tumors with presence of C/EBPα. It is possible that in these
NSCLCs the tumor suppressive effects of C/EBPα (29) may be overcome by loss of p53
function. These findings merit further investigation.
There was a non-statistical trend towards decreased C/EBPα expression in poorly
differentiated tumors. Since only 88 of the 164 tumors analyzed contained data regarding
histological differentiation, it is possible that in a larger sample a significant association
would emerge. A correlation of C/EBPα expression with differentiation is supported by its
role on airway epithelial differentiation as demonstrated by our group and others (27–30),
and had been seen in our initial C/EBPα study in lung cancer (29).
We were unable to identify a prognostic role for C/EBPα IHC status in the intergroup
E3590 study of resected stage II and III NSCLC. Both disease-free and overall survivals
were similar in the groups with weak or strong C/EBPα IHC. E3590 was a randomized trial
of adjuvant therapy (31), and we were able to evaluate if C/EBPα IHC could predict
response to radiation or platinum-based chemoradiation. C/EBPα IHC was not a predictive
marker. One possible hypothesis is that loss of C/EBPα is an early event in the initiation and
promotion of lung cancers with down-regulation of this protein and not related to the
metastatic potential or chemotherapeutic and radiation-resistant mechanisms of stage II and
IIIA NSCLCs (8,37). This hypothesis is currently being tested in mouse models with
conditional lung-targeted knockout of C/EBPα (28). It is possible that despite its lack of
significance as a prognostic marker in early stage NSCLC tumors, knowledge of a tumor’s
C/EBPα expression by IHC may be essential as a predictive marker for response to
therapies that aim at this transcription factor’s pathway.
In summary, our current IHC study of stage II and III resected NSCLC from the intergroup
study E3590 was able to identify down-regulation of C/EBPα in over half of the tumors,
with a higher magnitude of loss of expression in squamous cell carcinomas than
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adenocarcinomas. A trend was also observed between degree of differentiation and
expression status.
Down-regulation of C/EBPα is one of the most common events in lung cancer. In our cohort
of patients it was seen more often than p53 and K-ras mutations, which were present in 45
and 24% of samples, respectively (7). Further elucidation of C/EBPα mediated pathways in
NSCLC and search for agents that can either re-establish C/EBPα expression or bypass its
loss will likely enhance available therapeutic strategies for this malignancy.
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Immunohistochemical patterns for C/EBPα expression in E3590. Representative images: A)
Normal bronchial mucosa with strong C/EBPa staining of bronchial epithelium (3+). B)
Lack of C/EBPα staining (0) within tumor cells, C) Faint C/EBPα staining (1+), D)
Moderate staining (2+), E) Strong C/EBPα staining within tumor cells (3+, which is
comparable to that of the normal bronchial epithelium). (A, 100X; B, C, D and E, 400X).
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Survival curves in the weak and strong C/EBPα immunohistochemistry (IHC) groups. A)
Disease-free survival and B) Overall survival. The solid line represents the strong IHC (2+
or 3+) group and the dashed line represents the weak IHC group (0 or 1+).
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Survival curves in the weak and strong C/EBPα immunohistochemistry (IHC) groups by
treatment arm of E3590. A) Overall survival in arm A: radiotherapy; and B) Overall survival
in arm B: chemoradiation. The solid line represents the strong IHC (2+ or 3+) group and the
dashed line represents the weak IHC group (0 or 1+).
Costa et al. Page 12

























Costa et al. Page 13
Table 1
Comparison of clinical, pathologic and molecular characteristics by C/EBPα immunohistochemistry (IHC)
staining
0 or 1+ (weak)
C/EBPα IHC staining
(n=90)




Age median (range) in years 62 (35–81) 61 (35–77) 0.50
Sex – no. (%)
Male 55 (61) 37 (50) 0.16
TNM stage – no. (%)
II 37 (41) 35 (47) 0.43
IIIA 53 (59) 39 (53)
Histology – no. (%)
Squamous-cell 37 (41) 18 (24) 0.048†
Adenocarcinoma 44 (49) 42 (57)
Other 9 (10) 14 (19)
Treatment arm – no. (%)
Arm A (radiation) 47 (52) 36 (49) 0.75
Arm B (chemoradiation) 43 (48) 38 (51)
p53 mutation – no. (%)
Wildtype 52 (58) 33 (45) 0.16
Mutant 38 (42) 39 (53)
Not done 0 ( 0) 2 ( 3) *
K-ras mutation – no. (%)
Wildtype 64 (71) 48 (65) 0.61
Mutant 26 (29) 24 (32)
Not done 0 ( 0) 2 ( 3) *
*
Not done is excluded in the analysis
†
Reached statistical significance (≤ 0.05)
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